Among the most successful fund investment fields, there are Health Care, Medical Device. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Supira Medical.
The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in less than 2 deals every year. The important activity for fund was in 2018.
The typical case for the fund is to invest in rounds with 3 participants. The meaningful sponsors for the fund in investment in the same round are The Capital Partnership, Cormorant Asset Management.
|4G Ventures||Carmel, Indiana, United States|
|Collaborative Ventures||Concord, North Carolina, United States|
|Endeit Capital||Amsterdam, Noord-Holland, The Netherlands|
|Mahaka Group Media||-|
|Samsung SDS||New Jersey, Ridgefield Park, United States|
|Shenzhen Dachaoshan Equity Investment Fund Co Ltd||China, Guangdong, Shenzhen|
|Spider Capital||California, San Francisco, United States|
|Yunyihua Tongxun||China, Shanghai|
|$37M||29 Apr 2022||California, United States|
|$25M||10 Jan 2022||Campbell, California, United States|
|$30M||07 Jul 2021||California, United States|
|$35M||05 Mar 2020||California, United States|
|$15M||25 Apr 2018||California, United States|
– Tioga Medical, Inc. announced the initial closing of its committed $30M Series B financing.
– Led by The Capital Partnership (TCP), with participation from Cormorant Asset Management, AMED Ventures and Shifamed angel investors.
– The financing will be used to advance product development, support pre-clinical testing, and initiate clinical experience for the company’s novel transcatheter valve replacement technology.
– Myra Vision, a maker of a glaucoma treatment device and Shifamed portfolio company, closed its $17M Series A financing.
– The round was led by The Capital Partnership (TCP) with participation from Cormorant Asset Management and Shifamed angel investors.
– The new investment will be used to advance product development, scale infrastructure, and expand the team in order to support the development of its glaucoma treatment device.
4. We can moderate comments at any time.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.